The FDA's recent approval of Eli Lilly’s and Regeneron’s therapeutic monoclonal antibodies highlights the utility of neutralizing antibody detection systems.
The emergence of COVID-19, the disease caused by SARS-CoV-2, as a global pandemic has resulted in >60 million infections and >1.4 million deaths worldwide as of 11/30/2020. Studies have shown that SARS-CoV-2 uses an envelope homotrimeric spike glycoprotein to bind to and enter cells, primarily via the human angiotensin-converting enzyme 2 (ACE2) receptor. The receptor-binding domain (RBD) of SARS-CoV-2 spike protein binds with high affinity to ACE2, correlating with the efficient spread of SARS-CoV-2 among humans.
|